(Pixabay)
U.S.-based contract research organization Emmes is starting a mini buying spree as it buys up fellow CRO Orphan Reach.
This U.S.-based company, with offices in Ireland, Germany, India and Canada, will boost Emmes’ geographic footprint as well as deepen its offering in rare diseases. Financial details of the deal were not released.
This is also Emmes second acquisition in the past four months, coming after it snapped up Neox s.r.o., a European-based CRO.
“Our acquisition of Orphan Reach will accelerate our growth, establishing us as an industry leader in clinical research for orphan and rare diseases,” said Emmes’ CEO Christine Dingivan, M.D., who became its leader in the fall.
Emmes acquires rare diseases CRO Orphan Reach 13 May 2021 (Last Updated May 13th, 2021 12:21)
Emmes acquires Orphan Reach, which focuses on rare diseases, to boost its research and growth.
Share Article
Emmes intends to expand its orphan and rare disease research base. Credit: Pexels from Pixabay.
Global clinical research organisation (CRO) Emmes has acquired UK-based rare diseases CRO Orphan Reach to boost its research base for orphan and rare diseases, as well as to bolster growth opportunities.
The financial details of the transaction have not been disclosed.
Founded in 2002, Orphan Reach supports rare disease patients in about 70 countries. It works to expedite access to new treatments across various therapeutic areas.
Company's Second Major Acquisition Will Extend Orphan and Rare Disease Research Base and Growth Opportunities ROCKVILLE, Md., May 12, 2021 /PRNewswire/ Emmes, a global, full-service
/PRNewswire/ Emmes (the "Company"), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and.